Welcome to the Irish Medical Times website
This site is aimed at healthcare professionals.
Are you a healthcare professional?
NB: We use cookies to help personalise your web experience and comply with Irish healthcare law. Whatever your choice, you are agreeing to our use of cookies. Please close this browser tab if you don't want to proceed.
This site contains information, news and advice for healthcare professionals.
You have informed us that you are not a healthcare professional and therefore we are unable to provide you with access to this site.

May 28, 2016

Spiriva Respimat

Prescription. GMS. Sport Permitted.
Boehringer Ingelheim and Pfizer Healthcare are pleased to announce the introduction of Spiriva Respimat this month. The Respimat Soft Mist Inhaler is a new delivery device for Spiriva (tiotropium bromide).

The Respimat Soft Mist Inhaler represents a new generation in inhaler design. It is a propellant free device, which uses the energy generated from a spring. It delivers a slow moving, long lasting aerosol cloud, with high lung deposition. In clinical studies of inhaler devices, more patients preferred Respimat Soft Mist inhaler to other delivery devices tested; 81% of patients preferred the Respimat Soft Mist Inhaler compared to a standard MDI. Spiriva Respimat is indicated as a maintenance bronchodilator treatment to relieve symptoms of patients with COPD. The recommended dose of Spiriva Respimat is 5μg once daily, given as two consecutive puffs from the Respimat inhaler. In clinical trials, this dose has been shown to produce comparable therapeutic effects to Spiriva 18μg given by the HandiHaler (see New Clinical Evidence section). Should you need any further details please do not hesitate to contact Boehringer Ingelheim Ireland Ltd at (01) 2959620.